Orexigen Highest Since Dec. 8 on Likely Drug Approval
This article is for subscribers only.
Orexigen Therapeutics Inc. rose the most in almost two months after analysts said the company likely will receive U.S. regulatory approval of its obesity drug.
The U.S. Food and Drug Administration decision on the drug’s approval is expected today, according to analysts including Canaccord Genuity’s Adam Cutler in New York.